Elilily通过LillyDirect远程保健平台,通过单剂量小瓶降低Zepbound价格。 Eli Lilly reduces Zepbound price via single-dose vials through LillyDirect telehealth platform.

Elilly正在降低其流行减重药物Zepbound的价格,因为供需限制很高。 Eli Lilly is reducing the price of its popular weight loss drug, Zepbound, due to high demand and supply limitations. 该公司通过其远程保健平台LillyDirect提供单剂量小瓶Zepbound,该平台将病人与能够开出肥胖药的供应商连接起来。 The company is offering Zepbound in single-dose vials through its telehealth platform LillyDirect, which connects patients with providers capable of prescribing obesity drugs. 这种费用较低的选择方案可能会扩大保险计划不包括重力损失药品的病人的获得保险的机会,其中一些药品受到保险人的限制,或保险人为了管理上涨的费用而中止了承保范围。 This lower-cost option may expand access for patients whose insurance plans do not cover powerful weight-loss medications, some of which have been restricted or had coverage suspended by insurers to manage rising costs. 这一行动旨在打击提供减重药物的远程保健公司的竞争,并可能对它们构成挑战。 The move aims to combat competition from telehealth companies offering weight-loss drugs and could pose a challenge to them.